4.6 Article

Cellular restriction of retrovirus particle-mediated mRNA transfer

期刊

JOURNAL OF VIROLOGY
卷 82, 期 6, 页码 3069-3077

出版社

AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.01880-07

关键词

-

类别

资金

  1. Wellcome Trust [076608] Funding Source: Medline

向作者/读者索取更多资源

Analyzing cellular restriction mechanisms provides insight into viral replication strategies, identifies targets for antiviral drug design, and is crucial for the development of novel tools for experimental or therapeutic delivery of genetic information. We have previously shown that retroviral vector mutants that are unable to initiate reverse transcription mediate a transient expression of any sequence which replaces the gag-pol transcription unit, a process we call retrovirus particle-mediated mRNA transfer (RMT). Here, we further examined the mechanism of RMT by testing its sensitivity to cellular restriction factors and short hairpin RNAs (shRNAs). We found that both human TRIM5 alpha and, to a lesser extent, Fv1 effectively restrict RMT if the RNA is delivered by a restriction-sensitive capsid. While TRIM5 alpha restriction of RMT led to reduced levels of retroviral mRNA in target cells, restriction by Fv1 did not. Treatment with the proteasome inhibitor MG132 partially relieved TRIM5 alpha-mediated restriction of RMT. Finally, cells expressing shRNAs specifically targeting the retroviral mRNA inhibited RMT particles, but not reverse-transcribing particles. Retroviral mRNA may thus serve as a translation template if not used as a template for reverse transcription. Our data imply that retroviral nucleic acids become accessible to host factors, including ribosomes, as a result of particle remodeling during cytoplasmic trafficking.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

A pro B cell population forms the apex of the leukemic hierarchy in Hoxa9/Meis1-dependent AML

Anna Lieske, Eric Agyeman-Duah, Anton Selich, Nicole Doerpmund, Steven R. Talbot, Axel Schambach, Tobias Maetzig

Summary: Relapse in AML is a major challenge, partly due to the heterogeneity of leukemic stem cells (LSCs). This study shows that LSC potential in a murine AML model is present in three immunophenotypes: Lin(-)cKit(+) progenitor cells, Gr1(+)CD11b(+)cKit(+) myeloid cells, and lymphoid cells. Unexpectedly, a fraction of Lin(-) LSCs failed to regenerate Lym(+) LSCs and had reduced leukemogenic potential. However, Lin(-) LSCs capable of producing Lym(+) LSCs and Lym(+) LSCs triggered aggressive disease development, suggesting their high relapse-driving potential.

LEUKEMIA (2023)

Article Multidisciplinary Sciences

SARS-CoV-2 evolution influences GBP and IFITM sensitivity

Dejan Mesner, Ann-Kathrin Reuschl, Matthew V. X. Whelan, Taylor Bronzovich, Tafhima Haider, Lucy G. Thorne, Roberta Ragazzini, Paola Bonfanti, Greg J. Towers, Clare Jolly

Summary: The spike protein of SARS-CoV-2 requires proteolytic processing for viral entry. Guanylate-binding proteins (GBP) 2 and 5, interferon-inducible restriction factors, inhibit the infectivity of early-lineage isolates but not the VOCs Alpha and Delta. However, the Omicron variant is unique as it is sensitive to both GBP2/5 and IFITM1, 2, and 3.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2023)

Article Chemistry, Multidisciplinary

Podocalyxin-Like Protein 1 Regulates Pluripotency through the Cholesterol Biosynthesis Pathway

Wei-Ju Chen, Wei-Kai Huang, Sarshan R. Pather, Wei-Fang Chang, Li-Ying Sung, Han-Chung Wu, Mei-Ying Liao, Chi-Chiu Lee, Hsuan-Hui Wu, Chung-Yi Wu, Kuo-Shiang Liao, Chun-Yu Lin, Shang-Chih Yang, Hsuan Lin, Pei-Lun Lai, Chi-Hou Ng, Chun-Mei Hu, I-Chih Chen, Chi-Hsuan Chuang, Chien-Ying Lai, Po-Yu Lin, Yueh-Chang Lee, Scott C. Schuyler, Axel Schambach, Frank Leigh Lu, Jean Lu

Summary: This study identifies a membrane protein, PODXL, as a critical regulator of pluripotency in stem cells. It is found that PODXL plays a role in regulating cholesterol levels, which in turn affects the function and characteristics of pluripotent stem cells. Additionally, PODXL is involved in modulating actin network, SREBP transcription factors, and lipid raft dynamics.

ADVANCED SCIENCE (2023)

Article Oncology

Towards Novel Gene and Cell Therapy Approaches for Cervical Cancer

Robert Polten, Ivana Kutle, Jens Hachenberg, Ruediger Klapdor, Michael Morgan, Axel Schambach

Summary: Current treatments for cervical cancer include surgery, radiation, and chemotherapy, but complete cancer removal is not always possible and some cancer cells may be resistant to treatment. The use of immunotherapies, such as monoclonal antibodies and genetically modified immune cells, shows promise in improving patient survival.

CANCERS (2023)

Article Biochemistry & Molecular Biology

CD24 targeting with NK-CAR immunotherapy in testis, prostate, renal and (luminal-type) bladder cancer and identification of direct CD24 interaction partners

Christian Soehngen, David J. Thomas, Margaretha A. Skowron, Felix Bremmer, Markus Eckstein, Anja Stefanski, Marc D. Driessen, Gamal A. Wakileh, Kai Stuehler, Peter Altevogt, Dan Theodorescu, Ruediger Klapdor, Axel Schambach, Daniel Nettersheim

Summary: This study aimed to understand the molecular function of CD24 in vitro and evaluate the cytotoxic capacity of NK cell CAR against CD24 in urological tumor cells. The results showed that CD24 interacts with proteins involved in cell adhesion, ATP binding, phosphoprotein binding, and post-translational modifications. Treatment with NK-CD24-CAR cells significantly decreased cell viability and induced apoptosis specifically in CD24(+) tumor cells. This study provides a promising novel target for immune therapeutic approaches against urological malignancies.

FEBS JOURNAL (2023)

Article Hematology

Engineered human Diamond-Blackfan anemia disease model confirms therapeutic effects of clinically applicable lentiviral vector at single-cell resolution

Yang Liu, Ludwig Schmiderer, Martin Hjort, Stefan Lang, Tyra Bremborg, Anna Rydstroem, Axel Schambach, Jonas Larsson, Stefan Karlsson

Summary: This study generated a traceable RPS19-deficient cell model using CRISPR-Cas9 and homology-directed repair, and developed a gentle nanostraw delivery platform to edit the RPS19 gene in primary human cord blood derived CD34+ hematopoietic stem and progenitor cells. The edited cells showed impaired erythroid differentiation phenotype and activated cell cycle-related signaling pathways. This study demonstrates the potential of nanostraws as a gentle option for gene editing in primary hematopoietic stem and progenitor cells.

HAEMATOLOGICA (2023)

Letter Biochemistry & Molecular Biology

Access to gene therapy for rare diseases when commercialization is not fit for purpose

Thomas Fox, Juan Bueren, Fabio Candotti, Alain Fischer, Alessandro Aiuti, Arjan Lankester, Michael AGORA Initiative, Michael Albert, Maria Ester Bernardo, Marina Cavazzana, Stephan Ehl, Benedicte Neven, Johan Prevot, Axel Schambach, Julian Sevilla, Adrian Thrasher, Rob Wynn, Claire Booth

NATURE MEDICINE (2023)

Article Medicine, General & Internal

Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia

Robert Chiesa, Christos Georgiadis, Farhatullah Syed, Hong Zhan, Annie Etuk, Soragia Athina Gkazi, Roland Preece, Giorgio Ottaviano, Toni Braybrook, Jan Chu, Agnieszka Kubat, Stuart Adams, Rebecca Thomas, Kimberly Gilmour, David O'Connor, Ajay Vora, Waseem Qasim

Summary: Base editing technique has been used to inactivate genes and treat relapsed childhood T-cell leukemia with promising results.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Article Medicine, Research & Experimental

Persistent hematopoietic polyclonality after lentivirus-mediated gene therapy for Fabry disease

Amr H. Saleh, Michael Rothe, Dwayne L. Barber, William M. Mckillop, Graeme Fraser, Chantal F. Morel, Axel Schambach, Christiane Auray-Blais, Michael L. West, Aneal Khan, Daniel H. Fowler, Anthony C. Rupar, Ronan Foley, Jeffrey A. Medin, Armand Keating

Summary: We conducted a DNA insertion site analysis of peripheral blood samples from five male patients with Fabry disease to evaluate the risks of clonal dominance and leukemogenesis. Our study showed a polyclonal integration site spectrum in the patients, with no evidence of a dominant clone. Although vector integrations near proto-oncogenes were identified, they had low percentages of contributions and did not persist over time. Overall, lentivirus-mediated gene therapy for Fabry disease was not associated with the risk of leukemogenic transformation.

MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2023)

Article Oncology

Tumor Organoid and Spheroid Models for Cervical Cancer

Ivana Kutle, Robert Polten, Jens Hachenberg, Ruediger Klapdor, Michael Morgan, Axel Schambach

Summary: Appropriate testing models are crucial for finding effective personalized treatments for different cancers, including advanced cervical cancer. This review provides a comprehensive overview of the currently available 3D models of cervical cancer and their significance in pre-clinical and clinical studies. The review emphasizes the potential of 3D tumor models, such as spheroids and patient-derived organoids, in evaluating novel therapies, especially immunotherapies targeting tumor cells and modulating the tumor microenvironment.

CANCERS (2023)

Article Oncology

CAR-NK Cells Targeting HER1 (EGFR) Show Efficient Anti-Tumor Activity against Head and Neck Squamous Cell Carcinoma (HNSCC)

Juliette Nowak, Marco Bentele, Ivana Kutle, Katharina Zimmermann, Jonathan Lukas Luehmann, Doris Steinemann, Stephan Kloess, Ulrike Koehl, Willi Rossberg, Amed Ahmed, Dirk Schaudien, Lavinia Neubert, Jan-Christopher Kamp, Mark P. Kuehnel, Athanasia Warnecke, Axel Schambach, Michael Morgan

Summary: Despite poor prognosis and survival rates for head and neck squamous cell carcinomas (HNSCC), immunotherapy using CAR-NK cells targeting HER1/EGFR shows promise for HNSCC treatment. However, targeting HER1 alone is not sufficient to eliminate potential cancer stem cells. It is necessary to target multiple tumor-associated antigens to reduce high relapse rates in HNSCC.

CANCERS (2023)

Article Biotechnology & Applied Microbiology

CAR T cells as micropharmacies against solid cancers: Combining effector T-cell mediated cell death with vascular targeting in a one-step engineering process

Bianca Altvater, Sareetha Kailayangiri, Christian Spurny, Maike Fluegge, Jutta Meltzer, Lea Greune, Katja Urban, Christian Schwoeppe, Caroline Brand, Christoph Schliemann, Heike Hintelmann, Saliha Harrach, Wolfgang Hartmann, Hinrich Abken, Johannes Kuehle, Axel Schambach, Dennis Goerlich, Wolfgang E. Berdel, Claudia Rossig

Summary: To improve the effectiveness of CAR-engineered T cells in solid cancers, we developed a novel cell-based combination strategy involving an additional therapeutic mode of action. In this strategy, CAR T cells act as micropharmacies that produce a targeted coagulation protein called tTF-NGR, which induces blood clotting and hypoxia when it localizes to the vascular endothelial cells in tumor tissues. This approach aims to create locoregional tumor vascular infarction and combined immune-mediated and hypoxic tumor cell death.

CANCER GENE THERAPY (2023)

Article Medicine, Research & Experimental

Development of an in vitro genotoxicity assay to detect retroviral vector-induced lymphoid insertional mutants

Antonella L. Bastone, Violetta Dziadek, Philipp John-Neek, Friederike Mansel, Jenni Fleischauer, Eric Agyeman-Duah, Dirk Schaudien, Oliver Dittrich-Breiholz, Adrian Schwarzer, Axel Schambach, Michael Rothe

Summary: Safety assessment in retroviral vector-mediated gene therapy is challenging due to the risk of insertional mutagenesis. The authors developed two assays, IVIM and SAGA, to predict genotoxicity of integrating vectors. However, both assays have a myeloid bias, so the authors investigated lymphoid mutants and identified unique gene expression changes. The highly sensitive molecular readout based on gene expression will contribute to preclinical prediction of retroviral genotoxicity.

MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2023)

Article Cell Biology

TGF beta Inhibitor A83-01 Enhances Murine HSPC Expansion for Gene Therapy

Jenni Fleischauer, Antonella Lucia Bastone, Anton Selich, Philipp John-Neek, Luisa Weisskoeppel, Dirk Schaudien, Axel Schambach, Michael Rothe

Summary: Researchers developed cell culture conditions to maintain the stemness of murine hematopoietic stem and progenitor cells (HSPCs) and prevent differentiation. They used A83-01, pomalidomide, and UM171 (APU) to attenuate differentiation and preserve the stemness of HSPCs. Expanded HSPCs showed functional characteristics and could be used for retroviral vector testing and genotoxicity studies.
Meeting Abstract Oncology

CAR T cells as micropharmacies to induce locoregional tumor vascular infarction by antigen-specific delivery of tissue factor to the tumor microenvironment

Bianca Altvater, Sareetha Kailayangiri, Christian Spurny, Maike Flugge, Jutta Meltzer, Lea Greune, Christian Schwoppe, Caroline Brand, Christoph Schliemann, Wolfgang Hartmann, Hinrich Abken, Axel Schambach, Nicole Farwick, Wolfgang E. Berdel, Claudia Rossig

CANCER RESEARCH (2023)

暂无数据